
==== Front
Immun Inflamm Dis
Immun Inflamm Dis
10.1002/(ISSN)2050-4527
IID3
Immunity, Inflammation and Disease
2050-4527
John Wiley and Sons Inc. Hoboken

10.1002/iid3.70017
IID370017
Original Article
Original Article
Associations between single nucleotide polymorphisms of cytokines and hepatitis B virus‐related liver cirrhosis: A case‐control study
LI et al.
Li Yijun 1 2
Zhou Haowei 1 3
Wu Weikang 1
Zhang Wenhua 4
Ye Yancheng 5
Jia Wenling 4
Liang Chunhui 4
Tang Haitao 4
Wang Fengmei 4
Shao Zhongjun 1 13759981783@163.com

Yuan Xiaojie 1 yuan29136813@163.com

Zhang Weilu http://orcid.org/0000-0002-1405-4873
1 zhangweilu@126.com

1 Department of Epidemiology, Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, School of Public Health Fourth Military Medical University Xi'an China
2 Education Department of Surgery, Frist Affiliated Hospital Fourth Military Medical University Xi'an China
3 Department of Burns and Plastic Surgery, Second Affiliated Hospital Fourth Military Medical University Xi'an China
4 Clinical Drug Experiment Institution Gansu Wuwei Tumor Hospital Wuwei China
5 Hepatobiliary Center Gansu Wuwei Tumor Hospital Wuwei China
* Correspondence Weilu Zhang, Xiaojie Yuan, and Zhongjun Shao, Department of Epidemiology, Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi'an, China.
Email: zhangweilu@126.com, yuan29136813@163.com and 13759981783@163.com

24 9 2024
9 2024
12 9 10.1002/iid3.v12.9 e7001717 8 2024
06 1 2024
04 9 2024
© 2024 The Author(s). Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Abstract

Background and Aims

Various inflammatory and immune cytokines play key roles in the progression of hepatitis B virus (HBV)‐related liver cirrhosis (LC). This study explored the relationship between single nucleotide polymorphisms (SNPs) in cytokines with the combined effect of polymorphisms and gender‐polymorphisms interaction and LC risk.

Methods

In this study, a case–control design was used, samples were selected from 45 patients with hepatitis B‐related cirrhosis and 45 age‐gender‐matched chronic HBV‐infected patients without cirrhosis attending the tumor hospital of Wuwei Academy of Medical Sciences. Fifteen SNPs were examined using a real‐time polymerase chain reaction allelic discrimination system. Logistic regression was utilized to assess cytokine‐associated SNPs and the association between SNPs and LC progression in HBV‐infected patients.

Results

The multivariate‐adjusted logistic model revealed that the GG/AG dominant model (OR, 16.38; 95% CI, 1.13–236.70) and G allele (OR, 5.93; 95% CI, 0.98–36.01) of rs1800896 were associated with an increased risk of cirrhosis in CHB patients. Instead, rs2227306 CT presented a reduced cirrhosis risk (OR, 0.22; 95% CI, 0.04–1.38). Rs2055979 AA/AC was negatively associated with the risk of cirrhosis, potentially reversed in males (p = 0.021). Rs1799964 CC/CT was positively related to the risk of cirrhosis but reduced the risk of cirrhosis in males (OR, 0.13; 95% CI, 0.022–0.808; p = 0.028). Both rs1799964 TT and rs1799724 CT/TT genotype showed a synergistic effect in reducing the risk of cirrhosis with rs1800896 AA (OR, 0.08; 95% CI, 0.01–1.43 and OR, 0.12; 95% CI, 0.01–2.21).

Conclusion

Polymorphisms rs1800896 and rs2227306 are potentially associated with the risk of cirrhosis. For the first time, the study highlights that the rs2055979 AA/AC and rs1799964 CC/CT polymorphism interact with gender and its potential reversal of cirrhosis risk in males. Furthermore, rs1800896 AA showed a synergistic effect with rs1799964 TT and rs1799724 CT/TT to prevent the progression of HBV infection to cirrhosis.

hepatitis B virus
liver cirrhosis
single‐nucleotide polymorphism
Natural Science Foundation of Shaanxi Province2023‐JC‐QN‐0987 National Natural Science Foundation of China81773488 82273689 source-schema-version-number2.0
cover-dateSeptember 2024
details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:6.4.8 mode:remove_FC converted:24.09.2024
Li Y , Zhou H , Wu WK , et al. Associations between single nucleotide polymorphisms of cytokines and hepatitis B virus‐related liver cirrhosis: a case–control study. Immun Inflamm Dis. 2024;12 :e70017. 10.1002/iid3.70017

Yijun Li and Haowei Zhou contributed equally to this study and share the first authorship.
==== Body
pmc1 INTRODUCTION

Hepatitis B virus (HBV) infection, a global health concern, impacts approximately 316 million individuals worldwide. 1 China, as a typical developing country, is still facing a significant burden with an HBV prevalence of about 3.0% (95% CI, 2.1%–3.9%) or roughly 43.3 million people. 2 According to the World Health Organization definition, a prevalence between 5.0% and 7.9% is classified as a higher intermediate prevalence. Wuwei City, located in northwest mainland China, has been selected as a pilot site for HBV prevention and treatment programs due to its higher prevalence of HBV infection. With various prevention and treatment measures, the hepatitis B surface antigen‐positive rate in the area decreased from 7.2% (95% CI, 6.3%–8.1%) reported in 2010 to 4.1% in 2020. 3 , 4 This figure remains higher than the national average, and patients with chronic hepatitis B (CHB) are at significantly higher risk for developing liver cirrhosis (LC), which can further lead to hepatocellular carcinoma (HCC) and liver disease‐related mortality. Therefore, impeding CHB progression to LC is crucial for the patient's long‐term health.

Cytokines, which act as critical mediators, regulate inflammatory immune responses and affect the outcome of the HBV infection. 5 Single nucleotide polymorphisms (SNPs), as host factors, can influence cytokine expression. Cytokine‐associated SNPs have also been linked to the clinical outcomes of HBV infection. The IL‐1β TT genotype has been demonstrated to elevate the likelihood of HBV infection. 6 The IL‐4 CC genotype and the tumor necrosis factor (TNF‐α) TT genotype have been demonstrated to confer a decreased risk of HBV infection. 7 , 8 Both the IL‐12β CC genotype and the transforming growth factor (TGF‐β1) CC genotype have been identified to increase the risk of HCC infection. 9 , 10 HBV‐related LC, as an important phase of HBV infection, was found to be related to several SNPs of cytokines, such as the TT genotype of interleukin‐2 (IL‐2), 7 the TT genotype of IL‐6, 11 and the CC genotype of IL‐10. 12 These SNPs have been demonstrated to increase the risk of HBV‐related LC. However, the majority of studies have been independent discoveries of cytokine‐associated SNPs, and the combined effects of multiple SNPs and their association with HBV‐related LC are rare.

In addition to cytokines, cellular receptor polymorphisms have been identified as a factor in HBV infection. Sodium Taurocholate Cotransporting Polypeptide (NTCP), a sodium‐dependent bile acid transport protein that facilitates the movement of bile acids from the blood into hepatocytes, has been identified as a cellular receptor for HBV in host hepatocytes. It has been demonstrated that the rs2296651 GG genotype of NTCP is associated with an increased risk of LC. 13 Furthermore, the rs4646287 AA genotype has been identified to increase the risk of HCC infection. 14 Nevertheless, these findings require further cross‐validation by additional studies, and there are still other cytokines to be explored in the context of HBV‐related LC.

Therefore, this study aimed to investigate the associations between SNPs located in cytokine and NTCP genes and HBV‐related LC, particularly focusing on examining the combined effects of these polymorphisms and their interaction with gender.

2 MATERIALS AND METHODS

2.1 Participants

This was a case–control study. A total of 357 participants with CHB, who had previously tested positive for HBsAg for at least 6 months, were continuously enrolled from Gansu Wuwei Medical Academy Cancer Hospital between August 2018 and January 2021. Among them, 45 participants had previously been diagnosed with cirrhosis (the LC group). After excluding nine participants (seven anti‐HCV positive and two with persistently negative SNP results), and in a 1:1 ratio, participants without HCC or hepatic failure of the same sex and with an age difference of no more than 5 years during the same period were randomly selected as the CHB group. A flow chart of the selection and assignment process is presented in Figure S1. Cirrhosis diagnosis followed the criteria proposed in 2019, 15 which required the exclusion of noncirrhotic portal hypertension and the presence of at least two of the following five criteria: (1) signs of cirrhosis and/or portal hypertension by imaging; (2) esophageal and gastric varices by endoscopic examination; (3) liver cirrhosis by liver stiffness measure (LSM) (>17.5 kPa); (4) decreased albumin level (<35 g/L) and/or prolonged PT (>3 s compared with the control); (5) platelet count <100 × 109/L.

All research was approved by The Clinical Trial Ethics Committee of Gansu Wuwei Medical Academy Cancer Hospital (2024‐Ethics Approval‐10). All participants were fully informed about the study details, and written informed consent was obtained from the participants themselves or their legal guardians before their participation.

2.2 Data collection

Data was collected through structured questionnaire‐based, face‐to‐face interviews by trained investigators. Physical and serological examinations were performed at Gansu Wuwei Medical Academy Cancer Hospital. Liver function parameters were evaluated using standard laboratory tests, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBIL), direct bilirubin (DBIL), indirect bilirubin (IBIL), gamma‐glutamyl transpeptidase (GGT), and albumin (ALB) concentrations. Serological markers (including HBsAg, HBeAg, anti‐HBs, anti‐HBe, anti‐HBc, and anti‐hepatitis C virus) were tested using enzyme‐linked immunosorbent assay (ELISA) reagents (KHB). Serum HBV DNA levels were measured using a hybrid capture assay (DAAN gene) until 2019, thereafter using a PCR‐fluorescence probing assay (ABBOTT). LSM and controlled attenuation parameter (CAP) were obtained using the Fibroscan® (Echosens) system, which utilizes a one‐dimensional transient elastography technique.

2.3 Quantitative examination of pgRNA and HBcrAg

HBV pgRNA was detected by the RNA simultaneous amplification testing method based on real‐time fluorescence detection of RNA transcription‐mediated nucleic acid amplification (Shengxiang Biotechnology). 16 The assay has a linear measurement range from 2 to 9 log10 copies/mL, with levels below 2 log10 copies/mL considered negative for HBV pgRNA.

Serum HBcrAg was analyzed using the Lumipulse G HBcrAg chemiluminescence Enzyme Immunoassay (Fujirebio). This immunoassay measures the antigenic reactivity of three proteins: HBeAg, HBcAg, and core‐related protein p22cr (products of the HBV pre‐core/core gene sharing a 149‐amino‐acid sequence). The assay's linear measurement range spans from 3 to 7 log10 U/mL. Despite the machine's lowest sensitivity limit being 2 log10 U/mL, complete specificity was reached for values above 3 log10 U/mL, thus HBcrAg levels between 2 and 3 log10 U/mL were considered negative. Samples presenting HBcrAg above 7 log10 U/mL were diluted and retested with a specific reagent to quantify HBcrAg values.

2.4 Human SNPs

Genomic DNA was isolated from whole blood samples using Human Genome Whole Blood Extraction Kit (Tianlong). Thirteen SNPs related to cytokines (rs2055979 of IL‐21, rs3806798 of IL‐15, rs2069762 of IL‐2, rs1800795 of IL‐6, rs2227306 of CXCL8/IL‐8, rs1800469 of TGF‐β1, rs1800896 of IL‐10/IL‐19, rs1061624 of TNFRSF1B, rs1799724 of TNF‐α, rs12979860 of IFNL4/IL‐28B, rs1799964 of TNF‐α, rs1143634 of IL‐1β, rs1800872 of IL‐10/IL‐19) were assessed with TaqMan® MGB SNP Genotyping Kit (Fuyuan Biotechnology Co. Ltd) using a real‐time polymerase chain reaction (PCR) allelic discrimination system (Tianlong). The universal reaction conditions for cytokine‐related SNP genotyping were as follows: 5 μL DNA, 2 μL primer & probe premix, and 10 μL RealFAST Probe PCR mix made to a final volume of 25 μL with 8 μL double distilled water. The PCR cycle conditions consisted of an initial denaturation at 95°C for 5 min followed by 40 cycles at 95°C for 10 s and 60°C for 30 s. Primers for 13 SNPs were listed in Table S1. Shannon entropy (SE) of human SNPs was calculated according to the following formula, 17 where i represents the genotype and pi represents the percentage of each genotype. SE=−∑inpi×ln(pi).

In addition, we assessed two SNPs related to sodium taurocholate co‐transporting polypeptide (NTCP) (rs2296651 and rs4646287 of SLC10A1) by the TaqMan® SNP Genotyping Assay (ABI) according to manufacturer's instruction.

2.5 Statistical analysis

Variables were presented as means with corresponding standard deviations (SD), medians with quartiles, or as simple numbers with percentages, and were compared using Student's T test, Wilcoxon's test, standard χ 2 tests, or Fisher's Exact tests. The Hardy–Weinberg equilibrium was determined by the χ 2 test. In consideration of linkage disequilibrium and the combined effect of SNPs, the linkage disequilibrium (LD) between SNPs was calculated using the SHEsis online software platform (http://analysis.bio-x.cn), with r 2 as the coefficient and r 2 > 0.8 indicating a significant linkage disequilibrium between two loci. The associations between SNPs and LC risk were examined using univariate and multivariate logistic regression models, with results expressed as odds ratios (OR) with 95% confidence intervals (CI). A stratified analysis was performed and the interaction effect was examined according to gender. The interaction effect between SNPs was also analyzed. Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc) and with R software, version 4.3.0 (http://cran.r-project.org/). A p value of 0.05 was established as the threshold for statistical significance and a p value between 0.05 and 0.10 was considered to have potential statistical significance.

3 RESULTS

3.1 Baseline characteristic

Table 1 summarizes participants' characteristics, including demographic information, biochemical features, and virological data. Forty‐five individuals with CHB with a mean age of 55.4 (7.5) years and 45 individuals with LC with a mean age of 54.4 (8.1) years were enrolled in this study, which was not significantly different. The LC group had higher proportions of smoking, antiviral treatment, and higher levels of HBcrAg, ALT, AST, and LSM. However, the proportions of alcohol drinking and HBeAg(+), and the levels of HBV DNA, HBV RNA, and CAP were significantly lower than the CHB group.

Table 1 Clinicopathological characteristics of participants.

Characteristics	CHB (n = 45)	LC (n = 45)	p Value	
Age, years	55.4 ± 7.5	54.4 ± 8.1	0.543	
Gender, male (%)	30 (66.7)	30 (66.7)	1.000	
Smoking, n (%)	17 (37.8)	23 (51.1)	0.203	
Drinking, n (%)	5 (11.1)	2 (4.4)	0.434	
Antiviral treatment, n (%)	18 (40.0)	43 (95.6)	<0.001	
HBeAg+, n (%)	16 (35.6)	5 (11.1)	0.006	
HBV DNA, log10 IU/mL	3.1 (2.0–4.9)	2.0 (2.0–2.0)	<0.001	
HBV RNA, log10 IU/mL	3.1 (2.0–4.1)	2.0 (2.0–3.0)	0.002	
HBcrAg,a log10 U/mL	4.0 (3.0–7.2)	4.8 (3.4–5.5)	0.961	
ALT, IU/L	40.0 (25.9–71.0)	41.1 (23.8–61.3)	0.608	
AST, IU/L	30.0 (23.0–49.8)	37.4 (28.3–49.7)	0.108	
CAP, dB/m	235.0 (207.0–275.0)	218.0 (181.0–240.0)	0.015	
LSM, kPa	5.3 (3.8–7.6)	14.2 (8.7–18.0)	<0.001	
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CAP, controlled attenuation parameter; CHB, chronic hepatitis B; HBcrAg, hepatitis B c antigen; HBeAg, Hepatitis B e antigen; HBV, hepatitis B virus; LC, liver cirrhosis; LSM, liver stiffness measurement.

a HBcrAg results of six participants were missing, two in CHB, and four in LC group.

John Wiley & Sons, Ltd.

Surprisingly, HBV DNA, HBV RNA, and HBcrAg were highly correlated in CHB (r = 0.657, r = 0.694 and r = 0.683, p < 0.001, respectively), but not in LC participants. In the LC group, only a positive correlation between HBV RNA and HBcrAg (r = 0.376, p = 0.016) was observed (Figure 1). Multivariate logistic regression showed HBV RNA to be more representative of HBV cirrhosis than HBV DNA (Table S2). Moreover, factors such as antiviral treatment, and HBeAg status were also related to HBV‐related LC (Table S2).

Figure 1 Correlation analysis of HBV DNA, HBV RNA, and HBcrAg between the CHB and LC groups. (A) Association between HBV DNA and HBV RNA in CHB and LC groups. (B) Association between HBV DNA and HBcrAg in CHB and LC groups. (C) Association between HBV RNA and HBcrAg in CHB and LC groups. ***p < 0.001. *p < 0.05. CHB, chronic hepatitis B; LC, liver cirrhosis.

3.2 Distributions of the SNPs

The genotypic distribution of rs2055979, rs3806798, rs2069762, rs1800795, rs2227306, rs1800469, rs1800896, rs1061624, rs1799724, rs12979860, rs1799964, rs1143634, rs1800872, rs2296651, and rs4646287 polymorphism complied with the Hardye–Weinberg equilibrium (p > 0.05, Table S3). We genotyped fifteen polymorphisms in CHB and LC patients and depicted their genotypic distribution in Figure S2. Among them, rs2069762 showed a significant difference between the CHB and LC groups, with the LC group having a lower proportion of GG (p = 0.036). Meanwhile, rs1799964 and rs1800469 showed a probable difference between the CHB and LC groups, with the LC group having a higher proportion of CC (p = 0.054) and a lower proportion of TT (p = 0.086).

3.3 SNPs and HBV‐related LC

To evaluate the effect of cytokine‐related SNPs on HBV progression, we constructed univariate and multivariate‐adjusted logistic models for each SNP based on genotype, dominant and recessive model, and allele frequency (Tables 2, S4–S7). After adjusting for age, gender, antiviral treatment, HBeAg status, HBV RNA, HBcrAg, and alcohol drinking, rs1800896 GG/AG presented an increased risk of cirrhosis (OR, 16.38; 95% CI, 1.13–236.70; p = 0.040, Table 2). The G allele also showed an increased risk of cirrhosis (OR, 5.93; 95% CI, 0.98–36.01; p = 0.053, Table 2).

Table 2 Association between cytokines‐related SNPs and cirrhosis in chronic hepatitis B infection participants.

Genotype	CHB (n = 45)	LC (n = 45)	Univariate model	Multivariate modela	
OR (95% CI)	p Value	OR (95% CI)	p Value	
rs1800896	
AA	36 (80.0)	39 (86.7)	1.00		1.00		
AG	8 (17.8)	6 (13.3)	0.69 (0.22–2.19)	0.969	16.37 (1.13–236.40)	0.979	
GG	1 (2.2)	0 (0.0)	‐	‐	‐	‐	
Dominant	
AA	36 (80.0)	39 (86.7)	1.00		1.00		
GG/AG	9 (20.0)	6 (13.3)	0.62 (0.20–1.90)	0.399	16.38 (1.13–236.70)	0.040	
Recessive	
AA/AG	44 (97.8)	45 (100)	1.00		1.00		
GG	1 (2.2)	0 (0.0)	‐	‐	‐	‐	
Allele	
A	80 (88.9)	84 (93.3)	1.00		1.00		
G	10 (11.1)	6 (6.7)	0.57 (0.20–1.65)	0.300	5.93 (0.98–36.01)	0.053	
rs2227306	
CC	19 (42.2)	16 (35.6)	1.00		1.00		
CT	16 (35.6)	19 (42.2)	1.41 (0.55–3.61)	0.558	0.22 (0.04–1.38)	0.043	
TT	10 (22.2)	10 (22.2)	1.19 (0.40–3.57)	1.000	2.65 (0.25–27.80)	0.145	
Dominant	
CC	19 (42.2)	16 (35.6)	1.00		1.00		
TT/CT	26 (57.8)	29 (64.4)	1.33 (0.57–3.10)	0.517	0.53 (0.12–2.42)	0.410	
Recessive	
CC/CT	35 (77.8)	35 (77.8)	1.00		1.00		
TT	10 (22.2)	10 (22.2)	1.00 (0.37–2.70)	1.000	4.46 (0.51–38.96)	0.176	
Allele	
C	54 (60.0)	51 (56.7)	1.00		1.0		
T	36 (40.0)	39 (43.3)	1.15 (0.63–2.08)	0.650	1.11 (0.41–2.98)	0.839	
rs2069762	
TT	13 (28.9)	25 (55.6)	1.00		1.00		
TG	27 (60.0)	17 (37.8)	0.33 (0.13–0.81)	0.293	0.75 (0.16–3.51)	0.752	
GG	5 (11.1)	3 (6.7)	0.31 (0.06–1.52)	0.429	0.32 (0.02–4.43)	0.440	
Dominant	
TT	13 (28.9)	25 (55.6)	1.00		1.00		
GG/TG	32 (71.1)	20 (44.4)	0.33 (0.14–0.78)	0.012	0.66 (0.15–2.86)	0.574	
Recessive	
TT/TG	40 (88.9)	42 (93.3)	1.00		1.00		
GG	5 (11.1)	3 (6.7)	0.57 (0.13–2.55)	0.463	0.37 (0.03–4.63)	0.443	
Allele	
T	53 (58.9)	67 (74.4)	1.00		1.00		
G	37 (41.1)	23 (25.6)	0.49 (0.26–0.93)	0.028	0.68 (0.24–1.95)	0.477	
Abbreviations: A, adenine; C, cytosine; CHB, chronic hepatitis B; CI, confidence interval G, guanine; LC, liver cirrhosis; OR, odds ratio; T, thymine.

a Adjusting for age, gender, smoking, alcohol drinking, antiviral treatment, HBeAg status, HBV RNA, and HBcrAg.

John Wiley & Sons, Ltd.

In terms of genotype, only rs2227306 CT presented a reduced cirrhosis risk after adjusting for age, gender, antiviral treatment, HBeAg status, HBV RNA, HBcrAg, and alcohol drinking in the multivariate model (OR, 0.22; 95% CI, 0.04–1.38; p = 0.043, Table 2). Upon stratifying participants by the dominant model, individuals with the TT/CT genotype of rs2227306 exhibited lower levels of HBV DNA (Table S8).

Similarly, rs2069762 GG/TG as the dominant model (OR, 0.33; 95% CI, 0.14–0.78; p = 0.012) and the G allele (OR, 0.49; 95% CI, 0.26–0.93; p = 0.028) presented a reduced cirrhosis risk only in the univariate model (Table 2). No associations were observed with two SNPs related to NCTP during the liver cirrhosis progression in patients with chronic HBV infection (Table 2).

3.4 Gender difference

The interaction between gender and SNPs was further analyzed. A potential interaction was observed between gender and rs2055979, and rs1799964.

Rs2055979 AA/AC was negatively associated with the risk of cirrhosis, which appeared to reverse for male participants (p = 0.021, Table 3). However, when stratifying participants by gender, the multivariate‐adjusted regression analysis did not reveal a significant association between rs2055979 and cirrhosis for either gender (data not shown).

Table 3 Interaction analysis of rs2055979 with gender.

Parameter		β	SE	Wald χ 2	p Value	
Intercept		−3.979	3.923	1.029	0.310	
rs2055979	AA/AC	−0.715	0.575	1.543	0.214	
Gender	Male	−0.837	0.540	2.406	0.121	
rs2055979 × gender	AA/AC	1.606	0.696	5.322	0.021	
Age, years		0.024	0.052	0.202	0.653	
Antiviral treatment	Yes	3.426	1.060	10.449	0.001	
HBeAg, log10 IU/mL	+	−1.565	0.590	7.027	0.008	
HBV RNA, log10 IU/mL		−1.663	0.532	9.753	0.002	
HBcrAg, log10 U/mL		0.922	0.406	5.146	0.023	
Drinking	Yes	−0.609	0.763	0.637	0.425	
Abbreviations: C, cytosine; HBcrAg, hepatitis B c antigen; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; T, thymine.

John Wiley & Sons, Ltd.

Instead, rs1799964 CC/CT was positively associated with the risk of cirrhosis, which appeared to reverse for male participants (p = 0.093, Table 4). However, when stratifying participants by gender, the multivariate‐adjusted regression analysis showed that rs1799964 CC/CT reduced the risk of cirrhosis in males (OR, 0.13; 95% CI, 0.022–0.808; p = 0.028, Table S9).

Table 4 Interaction analysis of rs1799964 with gender.

Parameter		β	SE	Wald χ 2	p Value	
Intercept		−2.895	3.880	0.557	0.456	
rs1799964	CC/CT	0.119	0.485	0.061	0.806	
Gender	Male	−0.505	0.458	1.219	0.270	
rs1799964 × gender	CC/CT	−0.818	0.487	2.819	0.093	
Age, years		0.017	0.053	0.102	0.750	
Antiviral treatment		2.407	0.637	14.264	<0.001	
HBeAg, log10 IU/mL		−1.393	0.568	6.004	0.014	
HBV RNA, log10 IU/mL		−0.711	0.365	3.787	0.052	
HBcrAg, log10 U/mL		0.414	0.331	1.561	0.212	
Drinking	Yes	−0.301	0.903	0.111	0.739	
Abbreviations: C, cytosine; HBcrAg, hepatitis B c antigen; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; T, thymine.

John Wiley & Sons, Ltd.

3.5 Combination effect of SNPs

To understand the collective effect of gene polymorphisms associated with pro‐ and anti‐inflammatory cytokines on immunoregulation, we investigated the interactions between rs2069762, rs2227306, rs1799724, rs1799964, rs1800896, and rs1800872 in subjects with HBV infections. Pairwise LD analysis between different SNPs was conducted using SHEsis software (Figure 2). No significant LD was found among any pair of gene polymorphisms in our study population, indicating the SNPs were independent (r 2 < 0.5, Table S10). A potential combined effect to reduce the risk of cirrhosis was found with the rs1800896 AA genotype and the rs1799964 TT genotype (OR, 0.08; 95% CI, 0.003–1.700; p = 0.059, Table 5). Concurrently, a potential risk reduction for cirrhosis was observed with the combination of the rs1800896 AA genotype and the rs1799724 CT/TT genotype (OR, 0.12; 95% CI, 0.007–2.207; p = 0.098, Table 5).

Figure 2 Linkage disequilibrium tests among the rs2069762, rs2227306, rs1799724, rs1799964, rs1800896, and rs1800872 between the CHB and LC groups. CHB, chronic hepatitis B; LC, liver cirrhosis.

Table 5 Effects of interaction between rs1800896 and rs1799964/rs1799724 in patients with hepatitis B cirrhosis.

		OR (95% CI)	p Value	
rs1800896 AA	rs1799964 TT			
−	−	1.00	0.059	
−	+	0.197 (0.004, 10.201)	
+	+	0.076 (0.003, 1.700)	
+	−	0.011 (0.001, 0.331)	
rs1800896 AA	rs1799724 CT/TT			
−	−	1.00	0.098	
−	+	0.001 (0.001, 999.999)	
+	+	0.120 (0.007, 2.207)	
+	−	0.019 (0.001, 0.475)	
Abbreviations: A, adenine; C, cytosine; CI, confidence interval; OR, odds ratio; T, thymine.

John Wiley & Sons, Ltd.

4 DISCUSSION

Cytokines are key mediators in regulating the inflammatory immune response of the body and can be categorized as pro‐inflammatory or anti‐inflammatory based on their effects, whereas human SNPs can affect the expression or function of cytokines. It has been demonstrated that SNPs within coding regions have the potential to influence protein structure and function by modifying amino acids. Additionally, SNPs situated in noncoding regions that are situated in gene regulatory regions have the capacity to regulate gene expression by affecting transcription factors, which in turn alters the genetic mechanism and affects the pathophysiological process of diseases. 18 We observed GG/AG dominant model and G allele of rs1800896 were associated with an increased risk of cirrhosis in CHB patients. Instead, rs2227306 CT presented a reduced cirrhosis risk. Rs2055979 AA/AC was negatively associated with the risk of cirrhosis, potentially reversed in males. Rs1799964 CC/CT was positively related to the risk of cirrhosis but reduced the risk of cirrhosis in males. Both rs1799964 TT and rs1799724 CT/TT genotype showed a synergistic effect in reducing the risk of cirrhosis with rs1800896 AA.

Rs1800896 (IL‐10‐1082), one of the most important anti‐inflammatory and immunosuppressive factors regulating the antiviral immune response, is located at a common position in the proximal promoter region of the IL‐10 gene and can affect the transcription quality and quantity of IL‐10. 19 Our findings observed that CHB patients with the genotype GG/AG (OR, 16.38; 95% CI, 1.13–236.70) and allele G (OR, 5.93; 95% CI, 0.98–36.01) of IL‐10‐1082 were potentially at a higher risk of cirrhosis after adjusting for age, gender, antiviral treatment, HBeAg status, HBV RNA, HBcrAg, and alcohol drinking. Similar results were found by Liu et al. who discovered that allele G was potentially linked to an increased risk of liver cirrhosis in the Chinese population (OR, 2.14; 95% CI, 0.97–1.68). 20 However, other studies have reported the opposite results. For instance, Yao and colleagues found that the IL‐10‐1082 GA/AA genotype increased the risk of cirrhosis compared to the GG genotype (OR, 1.95; 95% CI, 1.01–3.59). 12 Similarly, Gao and colleagues reported a significantly higher risk of cirrhosis in HBV‐HCV patients with the AA genotype (OR, 4.26; 95% CI, 1.59–11.36). 21

There is another IL‐10 locus in our study, rs1800872, specifically located at IL‐10‐592. A meta‐analysis suggested that the IL‐10‐592 heterozygote model was an independent risk factor for LC development in Asian populations (OR, 1.40; 95% CI, 1.03–1.88). 22 Jin and colleagues discovered that the CC genotype heightened liver cirrhosis risk and was associated with chronic hepatitis B infection in the Chinese population (OR, 2.46; 95% CI, 1.35–4.42). 23 Moreover, Guo and colleagues found that the IL‐10 GCC haplotype (rs1800896, rs1800871, rs1800872) likely reduced the risk of cirrhosis in HBV‐HCV patients, despite no distinct association observed for these three SNPs in either the general or Asian population. 24 Magda Rybicka and colleagues also noted that the GCCT haplotype (−1082G/−819C/−592C/−1353T) increased the risk of developing cirrhosis (OR, 2.61; 95% CI, 1.58–4.30). 25 However, our study did not observe a correlation between IL‐10‐592 and the progression of cirrhosis in patients with chronic HBV infection or any synergistic effect between IL‐10‐592 and IL‐10‐1082. The discrepancies in the above‐mentioned results may be due to varying ethnicities, study designs, disease statuses, and sample sizes. What's more, genetic variant frequencies can also differ across populations from different regions, so further large‐scale studies are needed to confirm our findings.

Tumor necrosis factor (TNF) is a major pro‐inflammatory cytokine that not only promotes immune‐mediated virological control but also causes hepatocellular injury, cirrhosis, and ultimately HCC during the development of liver disease. 26 TNF‐α is produced by mononuclear macrophages. We examined two SNPs rs1799964 (TNF‐α−1031) and rs1799724 (TNF‐α−857) located in TNF‐α, in addition to three loci, rs1800630 (TNF‐α−863), rs1800629 (TNF‐α−308), and rs361525 (TNF‐α−238), which are located in the promoter regions of the genes and have been reported to influence susceptibility to HBV infection and chronic outcomes such as cirrhosis or HCC. 27 Previous studies linked the C allele with a heightened HBV infection risk. 8 , 28 Conversely, data from Northern Poland showed a higher proportion of the TT genotype among CHB patients. 29 However, an association between TNF‐α−1031 T/C and cirrhosis risk was not observed in our study. Notably, potential interaction was found when we built an interaction item for gender and TNF‐α−1031. The CC/CT genotype was positively associated with the risk of cirrhosis, but this association could be reversed in male participants. Meanwhile, TNF‐α−857 showed no association with the risk of cirrhosis in our study, aligning with a study by Panigrahi et al. 30 However, it has been shown that the TNF‐α−857 T allele was an independent risk factor for the development of HCC in patients with HBV‐associated LC (HR, 6.29; 95% CI, 1.62–24.43). 31 A meta‐analysis also showed a significant association between TNF‐α−857 C/T and HCC risk (OR, 1.31; 95% CI, 1.06–1.62). 27 These discrepancies may stem from limited sample sizes and differing genetic distribution frequencies across various genders or populations. Inconsistent results may arise due to small sample sizes and different genetic variation frequencies across various populations. Thus, comprehensive longitudinal studies with a larger scale are needed to further explore TNF‐α gene polymorphism in different regional populations, considering all other cirrhosis‐related risk factors to validate these observations.

Rs2227306 (IL‐8‐781), a member of the CXC chemokine superfamily, can elicit a wide range of pro‐inflammatory responses. Previous studies on the effect of IL‐8‐781 gene polymorphism on HBV‐associated cirrhosis are limited. It was shown that IL‐8‐781 TT gene polymorphism significantly reduced the risk of HCC (OR, 0.72; 95% CI, 0.57–0.92). 32 However, our study showed that IL‐8‐781 CT reduced the risk of cirrhosis (OR, 0.22; 95% CI, 0.04–1.38). When stratifying participants by IL‐8‐781 genotype, TT/CT genotype patients showed lower HBV DNA levels, which may also be the reason for the lower risk of LC.

Previous studies have evaluated the interactions between the pro‐inflammatory cytokines IL‐2‐330 (rs2069762), IFN‐γ+874 (rs2430561), and the anti‐inflammatory cytokines IL‐10‐592 (rs1800872), IL‐10‐1082 (rs1800896). 7 Therefore, we explored the effect of the pro‐inflammatory properties of IL‐2‐330 (rs2069762), IL‐8 (rs2227306), TNF‐α−857 (rs1799724), and TNF‐α−1031 (rs1799964) versus the anti‐inflammatory properties of IL‐10‐1082 (rs1800896), IL‐10‐592 (rs1800872) on the risk of cirrhosis. Our study demonstrated that rs1800896 AA and rs1799964 TT showed an interaction on reducing the risk of cirrhosis and a similar effect with rs1800896 AA and rs1799724 CT/TT genotype, suggesting IL‐10 and TNF‐α may have a synergistic effect in LC risk reduction. IL‐10 can exert its anti‐inflammatory effects by inhibiting the release of inflammatory factors from T cells, NK cells, and monocyte macrophages. This attenuates the extent of the hepatic inflammatory response. 33 Concurrently, research has demonstrated that IL‐10 can diminish the synthesis and secretion of TNF‐α by inhibiting the activation of the NF‐κB pathway. The NF‐κB signaling pathway represents a pivotal pathway for TNF‐α‐induced inflammatory responses, thereby regulating hepatocyte apoptosis and necrosis. 34 , 35

Furthermore, we investigated the influence of the interaction between gender and SNPs on the development of cirrhosis. Our study observed a potential interaction between gender and rs2055979, and rs1799964, which need more epidemiology and experimental studies to illustrate. It has been demonstrated that in women, the rs1799964 TT genotype in the high dietary inflammatory index group is associated with an elevated risk of gastric cancer (OR, 2.30; 95% CI, 1.27–4.24). 36 Furthermore, evidence indicates that the TC+CC genotype at the rs5275 locus of the COX‐2 gene is associated with a reduced risk of HCC in women (OR, 1.56; 95% CI, 1.03–2.37). 37 However, previous studies have demonstrated no gender‐specific associations between rs2055979 and cancer risk. Consequently, research on the correlation between gender and SNPs in cirrhosis remains limited and requires further investigation through a substantial number of studies.

Before offering any recommendations, it's essential to acknowledge the study's limitations. Firstly, our analysis was regionally confined to Wuwei City, and the study subjects were hospital‐based populations, leading to potential selection bias and geographical limitations. Secondly, we didn't consider the likelihood of gene‐environment interactions or linkage disequilibrium between gene polymorphisms. Lastly, our study's relatively small sample size might have limited the statistical power to identify group differences. Therefore, larger‐scale studies in various ethnic groups are necessary to corroborate our findings.

5 CONCLUSION

In summary, this study investigated the association between SNPs and the risk of HBV‐related LC. Findings suggested a potential association between the risk of cirrhosis with rs1800896 and rs2227306 polymorphisms. For the first time, the study highlights that the rs2055979 AA/AC and rs1799964 CC/CT polymorphism interact with gender and its potential reversal of cirrhosis risk in males. Notably, we focused on the combined effects of genetic polymorphisms, demonstrating that both rs1799964 TT and rs1799724 CT/TT genotypes showed a synergistic effect in reducing the risk of cirrhosis with rs1800896 AA, potentially inhibiting the progression of HBV infection to cirrhosis.

AUTHOR CONTRIBUTIONS

Weilu Zhang, Xiaojie Yuan, and Zhongjun Shao designed the study and revised the manuscript. Yijun Li analyzed the data. Haowei Zhou and Xiaojie Yuan did an SNP laboratory examination. Yijun Li and Xiaojie Yuan wrote the manuscript. Weikang Wu collected blood samples and did an HBV‐related biomarkers examination. Wenhua Zhang and Yancheng Ye managed the cohort. Wenling Jia, Chunhui Liang, Haitao Tang, and Fengmei Wang collected data. All authors read and approved the final manuscript.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The Clinical Trial Ethics Committee of Gansu Wuwei Medical Academy Cancer Hospital (2024‐Ethics Approval‐10). The patients/participants provided written informed consent to participate in this study.

Supporting information

Supporting information.

ACKNOWLEDGMENTS

The authors thank the investigators and the participants who made this cohort study possible. This study was supported by the Natural Science Foundation of Shaanxi Province (2023‐JC‐QN‐0987) and the National Natural Science Foundation of China (General Program 82273689, 81773488).

DATA AVAILABILITY STATEMENT

Original contributions generated for this study are included in the article/Supporting Information. Further inquiries can be directed to the corresponding authors.
==== Refs
REFERENCES

1 GBD 2019 Hepatitis B Collaborators . Global, regional, and national burden of hepatitis B, 1990‐2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7 (9 ):796‐829.35738290
2 Liu Z , Lin C , Mao X , et al. Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta‐analysis of 3740 studies and 231 million people. Gut. 2023;72 (12 ):2354‐2363.37798085
3 Ji Z , Wang T , Shao Z , et al. A population‐based study examining hepatitis B virus infection and immunization rates in Northwest China. PLoS One. 2014;9 (5 ):e97474.24832483
4 Ye S , Guo Z , Ji Z . Influence of construction of demonstration area for viral hepatitis B prevention and treatment on epidemiological characteristics in Wuwei city. Bull Dis Control Prev. 2024:1‐4.
5 Li X , Liu X , Tian L , et al. Cytokine‐mediated immunopathogenesis of hepatitis B virus infections. Clin Rev Allergy Immunol. 2016;50 (1 ):41‐54.25480494
6 Dinarello CA . Overview of the IL‐1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281 (1 ):8‐27.29247995
7 Gao Q , Xie JX , Wang L , et al. Interaction effects among IFN‐γ+874, IL‐2‐330, IL‐10‐1082, IL‐10‐592 and IL‐4‐589 polymorphisms on the clinical progression of subjects infected with hepatitis B virus and/or hepatitis C virus: a retrospective nested case‐control study. BMJ Open. 2017;7 (8 ):e013279.
8 Fletcher GJ , Samuel P , Christdas J , et al. Association of HLA and TNF polymorphisms with the outcome of HBV infection in the South Indian population. Genes Immun. 2011;12 (7 ):552‐558.21593777
9 Wu J , Hsu H , Chiu Y , et al. The effects of cytokines on spontaneous hepatitis B surface antigen seroconversion in chronic hepatitis B virus infection. J Immunol. 2015;194 (2 ):690‐696.25505294
10 Li W , Yu X , Chen X , et al. HBV induces liver fibrosis via the TGF‐β1/miR‐21‐5p pathway. Exp Ther Med. 2020;21 (2 ):169.33456536
11 Xia C , Zhu W , Huang C , et al. Genetic polymorphisms of interleukin‐6 influence the development of hepatitis B virus‐related liver cirrhosis in the Han Chinese population. Infect Genet Evol. 2020;84 :104331.32353512
12 Yao L , Xing S , Fu X , et al. Association between interleukin‐10 gene promoter polymorphisms and susceptibility to liver cirrhosis. Int J Clin Exp Pathol. 2015;8 (9 ):11680‐11684.26617910
13 Su Z , Li Y , Liao Y , et al. Association of the gene polymorphisms in sodium taurocholate cotransporting polypeptide with the outcomes of hepatitis B infection in Chinese Han population. Infect Genet Evol. 2014;27 :77‐82.25010264
14 Li N , Zhang P , Yang C , et al. Association of genetic variation of sodium taurocholate cotransporting polypeptide with chronic hepatitis B virus infection. Genet Test Mol Biomarkers. 2014;18 (6 ):425‐429.24735529
15 Chinese Society of Infectious Diseases in Chinese Medical Association, Chinese Society of Hepatology in Chinese Medical Association . The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Chin J Hepatol. 2019;27 (12 ):938‐961.
16 Hu S , Li X , Sun Y , et al. Short‐term weight loss decreased the risk of chronic kidney disease in men with incident nonalcoholic fatty liver disease. Obesity. 2022;30 (7 ):1495‐1506.35730626
17 Shannon CE . A mathematical theory of communication. Bell Syst Tech J. 1948;27 :379‐423.
18 Liu C , Yu D , Lin D. Progress in single nucleotide polymorphism with cancer susceptibility and its clinical application. Chin J Lab Med. 2012;35 (7 ):579‐584.
19 Zhang Y , Chen L , Chen H . Associations between polymorphisms in IL‐10 gene and the risk of viral hepatitis: a meta‐analysis. Gut Pathog. 2020;12 :36.32742307
20 Liu Y , Yu M , Zhang A , et al. Interleukin‐10 gene promoter polymorphism and risk of liver cirrhosis. Genet Mol Res. 2015;14 (1 ):1229‐1234.25730061
21 Gao QJ , Liu DW , Zhang SY , et al. Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. World J Gastroenterol. 2009;15 (44 ):5610‐5619.19938203
22 Zheng M , Fang W , Yu M , et al. IL‐6 and IL‐10 gene polymorphisms and cirrhosis of liver risk from a comprehensive analysis. BMC Endocr Disord. 2021;21 (1 ):242.34886817
23 Jin X , Wang Y , Yan T , et al. Interleukin‐10 gene promoter polymorphism and susceptibility to liver cirrhosis. Hepatogastroenterology. 2014;61 (130 ):442‐446.24901158
24 Guo P , Jin J , Sun X . Influence of IL10 gene polymorphisms on the severity of liver fibrosis and susceptibility to liver cirrhosis in HBV/HCV‐infected patients. Infect Genet Evol. 2015;30 :89‐95.25514046
25 Rybicka M , Woziwodzka A , Sznarkowska A , et al. Genetic variation in IL‐10 influences the progression of hepatitis B infection. Int J Infect Dis. 2020;96 :260‐265.32387446
26 Valaydon Z , Pellegrini M , Thompson A , P , et al. The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. Clin Transl Immunol. 2016;5 (12 ):115.
27 Wungu CDK, Ariyanto FC, Prabowo GI, et al. Association between five types of tumor necrosis factor‐α gene polymorphism and hepatocellular carcinoma risk: a meta‐analysis. BMC Cancer. 2020;20(1):1134.
28 Wei Y , Zhao Z , Wang Z , Tang Z , et al. Relationships between IL‐1β, TNF‐α genetic polymorphisms and HBV infection: a meta‐analytical study. Gene. 2021;791 :145617.33775848
29 Woziwodzka A , Rybicka M , Sznarkowska A , et al. TNF‐α polymorphisms affect persistence and progression of HBV infection. Mol Genet Genomic Med. 2019;7 (10 ):00935.
30 Panigrahi R , Sarkar N , Biswas A , et al. Association of TNF‐α promoter polymorphism with HBV associated disease outcome among HBV infected patients from Orissa, Southern part of East India. J Clin Exp Hepatol. 2014;4 (3 ):202‐208.25755561
31 Jin YJ , Lee D , Chung YH , et al. Tumor necrosis factor‐alpha gene polymorphism associated with development of hepatitis B virus‐associated hepatocellular carcinoma. J Clin Gastroenterol. 2015;49 (8 ):e76‐e81.25319734
32 Zhang M , Fang T , Wang K , et al. Association of polymorphisms in interleukin‐8 gene with cancer risk: a meta‐analysis of 22 case–control studies. Onco Targets Ther. 2016;9 :3727‐3737.27382310
33 Wang Z , Qin H , Wang J , et al. Advances in the dual immunoregulatory role of interleukin‐10 and its application in anti‐inflammation. J Qingdao Univ. 2023;59 (2 ):313‐316.
34 Li YJ . Role of the Hedgehog Signaling Pathway in Acute Pancreatitis and Its Effects on TNF‐α, IL‐10 in rats. Hebei Medical University. 2015.
35 Wang Z, Tang J, Chen J, et al. The role and significance of tumor necrosis factor‐α in malignant tumor. J Clin Med Pract. 2023;27 (4 ):138‐143.
36 Kim J , Lee J , Choi IJ , et al. TNF genetic polymorphism (rs1799964) may modify the effect of the dietary inflammatory index on gastric cancer in a case‐control study. Sci Rep. 2020;10 (1 ):14590.32883994
37 Fan X , Qiu X , Yu H, et al. Association of COX‐2 gene SNPs with the risk of hepatocellular carcinoma. Chin J Cancer Prev Treat. 2011;18 (6 ):405‐409.
